Andrew Rowland
Overview
Explore the profile of Andrew Rowland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
2674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gao Y, Cheng A, Li L, Parent N, Kichenadasse G, Karapetis C, et al.
Int J Cancer
. 2025 Mar;
PMID: 40079683
The use of Immune checkpoint inhibitors (ICIs) as monotherapy for patients with hepatocellular carcinoma (HCC) has been associated with an increased risk of hyperprogressive disease (HPD), the occurrence of which...
2.
Menz B, Modi N, Abuhelwa A, Ruanglertboon W, Vitry A, Gao Y, et al.
Eur J Cancer
. 2025 Feb;
218:115274.
PMID: 39922126
Recent advancements in large language models (LLMs) enable real-time web search, improved referencing, and multilingual support, yet ensuring they provide safe health information remains crucial. This perspective evaluates seven publicly...
3.
Sorich M, Manning-Bennett A, Li L, Shahnam A, Kichenadasse G, Karapetis C, et al.
Target Oncol
. 2025 Jan;
PMID: 39777634
Background: Tumour mutational burden (TMB) is an established biomarker for patients treated with immune checkpoint inhibitors (ICIs). The optimal TMB cut-off is uncertain. It is also uncertain whether there is...
4.
Arsanious J, Rowland A, Sorich M, Hopkins A, Alfred S, Rowland A
J Clin Pharmacol
. 2024 Nov;
PMID: 39604049
Intravenous midazolam is frequently used for procedural sedation. Use of ritonavir containing antivirals in patients requiring procedural sedation with intravenous midazolam is postulated to increase the risk or prolong the...
5.
Modi N, Li L, Logan J, Wiese M, Abuhelwa A, McKinnon R, et al.
Clin Trials
. 2024 Oct;
:17407745241286147.
PMID: 39410781
Background: Amid growing emphasis from pharmaceutical companies, advocacy groups, and regulatory bodies for sharing of individual participant data, recent audits reveal limited sharing, particularly for high-revenue medicines. Therefore, this study...
6.
Menz B, Kuderer N, Chin-Yee B, Logan J, Rowland A, Sorich M, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2434997.
PMID: 39312237
Importance: With the growing use of large language models (LLMs) in education and health care settings, it is important to ensure that the information they generate is diverse and equitable,...
7.
Newman L, Useckaite Z, Wu T, Sorich M, Rowland A
Br J Clin Pharmacol
. 2024 Jul;
90(12):3146-3159.
PMID: 39078327
Aims: Drug exposure and response is determined by pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Interindividual differences in abundance of drug metabolizing enzymes (DMEs) and drug target proteins underpin PK and...
8.
Newman L, Useckaite Z, Rowland A
J Extracell Biol
. 2024 Jun;
1(9):e56.
PMID: 38938773
Extracellular vesicles (EVs) are membrane-bound nanosized particles released by cells into bodily fluids containing an array of molecular cargo. Several characteristics, including stability and accessibility in biofluids such as blood...
9.
Modi N, Swain S, Buyse M, Kuderer N, Rowland A, Rockhold F, et al.
J Clin Oncol
. 2024 Jun;
42(32):3773-3777.
PMID: 38917375
Unlocking the full potential of clinical trials through comprehensive CSR and IPD sharing can revolutionize cancer care, enhance safety evaluations, and reduce bias in systematic reviews. It is time for...
10.